25.49

25.49 (-0.41%)

As of Mar 06, 2024

ANAPTYSBIO, INC [ANAB]

Source: 

Company Overview

We are a clinical stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation (“SHM”), and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development of our proprietary product candidates, and where applicable, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights.

CountryUS
Headquarterssan diegocalifornia
Phone Number(858) 362-6295
Industrypharmaceutical preparations
CEODaniel Faga
Websitewww.anaptysbio.com